Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/11/2019
SIETES contiene 92834 citas

 
 
 1 a 20 de 98 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]
2.Enlace a cita original Cita con resumen
Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, Bunch KJ, Murphy MFG, Sutcliffe AG. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ 2018;362:k2644. [Ref.ID 102818]
3.Enlace a cita original Cita con resumen
Anónimo. Flutamida: casos graves de hepatotoxicidad asociados al uso fuera de las condiciones autorizadas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:27 de abril. [Ref.ID 101552]
4. Cita con resumen
Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]
6. Cita con resumen
D'Amico AV, Chen M-H, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 2015;314:1291-3. [Ref.ID 99525]
7. Cita con resumen
Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gómez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens Jr FL, Gelber RD, Hortobagyi GN, Albain KS, for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32. [Ref.ID 98930]
8. Cita con resumen
Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2014;291:2713-9. [Ref.ID 97706]
9. Cita con resumen
Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014;348:g1752. [Ref.ID 97481]
10. Cita con resumen
Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. BMJ 2014;348:g129. [Ref.ID 97218]
11. Cita con resumen
Anónimo. Fibromyomes utérins hémorragiques. Adapter le traitement à chaque femme. Prescrire 2014;34:115-22. [Ref.ID 97129]
12. Cita con resumen
Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013;310:289-96. [Ref.ID 95834]
13. Cita con resumen
Hyde R. Germany launches investigation into human trials scandal. Lancet 2013;382:115-6. [Ref.ID 95826]
15.Tiene citas relacionadas
Stewart EA. Uterine fibroids and evidence-based medicine - Not an oxymoron. N Engl J Med 2012;366:471-3. [Ref.ID 92307]
16.Tiene citas relacionadas Cita con resumen
Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Kouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osteroh I, Loumaye E, for the PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32. [Ref.ID 92305]
17.Tiene citas relacionadas
Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA 2011;306:2382-3. [Ref.ID 91670]
18. Cita con resumen
Anónimo. Prises de poids d'origine médicamenteuse. Prescrire 2011;31:748-52. [Ref.ID 91601]
19. Cita con resumen
Anónimo. Histréline. Nième agoniste de la gonadoréline, sans plus. Prescrire 2011;31:728. [Ref.ID 91595]
20.
Anónimo. Drugs for ovulation induction. Med Lett Drugs Ther 2011;53:86-8. [Ref.ID 91381]
Seleccionar todas
 
 1 a 20 de 98 siguiente >>